Inflammatory Bowel Disease Market Set to Reach $53.5 Billion by 2035

Inflammatory bowel disease market was valued at $31.6 billion in 2025 and is projected to reach $53.5 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2026-2035). Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is emerging as a significant global health challenge, driven by steadily rising incidence and prevalence across both developed and developing regions. In many industrialized countries, it is estimated that more than 1% of the population will be living with IBD by 2025, reflecting a long-term compounded prevalence trend. Current global estimates indicate that IBD affects over 7 million individual globally, with prevalence continuing to increase across all age groups, including children and adolescents. Systematic analyses report an approximate global prevalence of 229.7 cases per 100,000 population, with continued growth anticipated into and beyond 2025. In the United States alone, nearly three-quarters of a million people are living with Crohn’s disease. Globally, Crohn’s disease and ulcerative colitis collectively affect approximately 6 to 8 million individuals. Regional dynamics show that newly industrialized countries in Asia and Latin America are transitioning from historically low prevalence toward rapid growth, contributing to overall global case expansion. This rising patient pool is directly driving demand for pharmaceutical therapies, biologics, diagnostic tools, and specialized clinical care. Expanding healthcare infrastructure, increasing awareness, and government initiatives in emerging economies are further facilitating market adoption. As the global patient population grows, the IBD market is projected to witness robust revenue expansion, creating opportunities for pharmaceutical companies, healthcare providers, and diagnostic service providers. Overall, the increasing burden of IBD is translating into both clinical urgency and substantial commercial potential globally.

Browse the full report description of “Inflammatory Bowel Disease Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis (UC) and Crohn’s Disease (CD)), by Drug Class (Aminosalicylates, Corticosteroids, Immunosuppressants, Biologics, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/ibd-inflammatory-bowel-disease-market

Key Players and Recent Developments in the Global Inflammatory Bowel Disease Market

The global inflammatory bowel disease (IBD) market is led by major pharmaceutical companies developing advanced biologics and targeted therapies to address chronic gastrointestinal conditions. Prominent players include AbbVie Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company Ltd., among others. These companies focus on developing therapies that improve patient outcomes, reduce disease flare-ups, and offer safer long-term management options for ulcerative colitis and Crohn’s disease.

• In August 2025, the National Institute for Health and Care Excellence approved guselkumab (Tremfya) for use on the NHS as a treatment option for patients with moderate to severe ulcerative colitis or Crohn’s disease who have not responded to other therapies. The recommendation enables clinicians to prescribe the biological therapy for individuals experiencing inadequate response or intolerable side effects from existing treatments.

• In January 2025, Eli Lilly and Company announced FDA approval of Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults, expanding its use to both major types of inflammatory bowel disease. Approval was based on Phase 3 VIVID-1 trial results demonstrating significant clinical remission and endoscopic response at one year, with durable outcomes maintained through two years of continuous treatment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Disease Type
• Drug Class
• Distribution Channel
• Competitive Landscape – AbbVie Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Inflammatory Bowel Disease Market Report Segment

By Disease Type

• Ulcerative Colitis (UC)
• Crohn’s Disease (CD)

By Drug Class

• Aminosalicylates
• Corticosteroids
• Immunosuppressants
• Biologics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Inflammatory Bowel Disease Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ibd-inflammatory-bowel-disease-market